Home > Press > All Star Analysts Portfolio highlights: AMETEK, Cephalon, Helix Energy Solutions and Marriott Intíl
Zacks.com just released its latest additions and deletions to its proprietary All Star Analyst portfolio. Members on this exclusive list include AMETEK, Inc. (NYSE: AME), Cephalon, Inc. (NASDAQ: CEPH), Helix Energy Solutions (NYSE: HLX) and Marriott International, Inc. (NYSE: MAR). View the entire list of stocks on the All Star Analyst portfolio at http://at.zacks.com/?id=510
All Star Analysts Portfolio highlights: AMETEK, Cephalon, Helix Energy Solutions and Marriott Intíl
Chicago, IL | Posted on August 17th, 2007
This exclusive portfolio represents all stocks with a Strong Buy rating from at least four analysts with a 5-Star All Star ranking. These are the brokerage analysts whose stock recommendations proved to be the most profitable for investors. Since July 2002, this portfolio has generated an annualized return of 7.53%. Here is a synopsis of why these stocks are in the All Star Analysts Portfolio:
AMETEK, Inc. (NYSE: AME) announced earlier this week that it acquired CAMECA SAS from an investment group led by the Carlyle Group for approximately $112 million. CAMECA SAS is a French manufacturer of high-end elemental analysis systems used in advanced lab research, semiconductor and nanotechnology applications. According to AMETEK, the acquisition significantly broadens its technical capabilities in differentiated, high-end analytical instrumentation. AMETEK remains a member of the All Star Analyst Portfolio. For its second quarter, the company posted earnings per share of 54 cents on sales of $519.5 million, compared to the previous year's 43 cents on $450.6 million. The earnings result bettered the consensus by 3.9% while sales growth was 15%.
Cephalon, Inc. (NASDAQ: CEPH) recently announced positive results for a trial of FENTORAģ in the treatment of breakthrough pain associated with a broad range of chronic, non-cancer pain conditions. The drug has already been approved to treat pain in cancer patients. The company plans to submit the data to the FDA in the fourth quarter as part of its supplemental New Drug Application. The study was a double-blind, placebo-controlled, variable dose Phase 3 trial, which included 148 patients. Cephalon is an international biopharmaceutical company with a focus on four core therapeutic areas: central nervous system, pain, oncology and addiction. It remains a member of the All Star Analyst Portfolio.
Helix Energy Solutions (NYSE: HLX) is an international offshore energy company that provides development solutions and other key life of field services to the open energy market as well as to its own oil and gas business unit. The company's second quarter was challenging, but it was able to put together some solid numbers. Earnings per share of 70 cents moved past the consensus by almost 8% while revenues advanced by $105.6 million to $410.6 million. Revenue growth was driven primarily by an increase in oil and gas sales of $61 million, thanks mainly to the production added from the acquisition of Remington Oil & Gas.
Marriott International, Inc. (NYSE: MAR) recently announced that its Board approved an increase in its stock repurchase authorization by 40 million shares, bringing the total purchase authorization to approximately 51 million shares. At the same time, the lodging giant declared a quarterly cash dividend of 7.50 cents per share of common stock, payable Oct 23 to shareholders of record as of Sep 6. The company has paid a dividend in every quarter since late 1977. Marriott International remains one of the All Stars' favorite names in its industry.
Discover all the current All Star Analyst rankings and top analyst recommendations at http://at.zacks.com/?id=511
About Zacks All Star Analyst Survey
To learn which brokerage analysts are the best in their field and what stocks they're recommending today, see the Zacks All Star Analyst survey. This exclusive survey, created with Fortune Magazine, reveals the "Best-of-Breed" brokerage analysts. They are the select group of winners from the universe of brokerage analysts - the ones who consistently beat the street - the few you should be following now. Visit the Zacks All Star Survey to find the best analysts and their top stock recommendations at http://at.zacks.com/?id=512
Top recommendations from All Star Analysts Highlighted in FREE Investment Newsletter
Each week, Zacks.com highlights investment insight and favorite recommendations from All Star Analysts and other leading investment experts. This is all part of our FREE e-mail newsletter, "Profit from the Pros." The only way to get these powerful insights is with a FREE subscription to the "Profit from the Pros" investment newsletter. Register for a free subscription at http://at.zacks.com/?id=513
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros http://at.zacks.com/?id=514
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
*The S&P 500 Index is a well-known, unmanaged index of the prices of 500 large-company common stocks, mainly blue-chip stocks, selected by Standard & Poor's. The S&P 500 Index assumes reinvestment of dividends but does not reflect advisory fees. An investor cannot invest directly in an index.
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
For more information, please click here
Copyright © Business Wire 2007
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Harris & Harris Group Notes ABSMaterials' Series B Financing November 22nd, 2013
Harris & Harris Group Letter to Shareholders on Website November 18th, 2013
Harris & Harris Group Reports Financial Statements as of September 30, 2013 November 12th, 2013
Harris & Harris Group Notes CordenPharma's Acquisition of Ancora's Carbohydrate Synthesis Platform and Corporate Name November 7th, 2013
Stanford engineers show how to optimize carbon nanotube arrays for use in hot spots December 2nd, 2013
Architects of a nanoworld behind the screens November 29th, 2013
Making a gem of a tiny crystal: Slowly cooled DNA transforms disordered nanoparticles into orderly crystal November 27th, 2013
SEMATECH to Exhibit and Present at SEMICON Japan 2013 November 26th, 2013
How UK wonder substance graphene can't and won't benefit UK: Once a research-rich economy the UK has fallen behind in innovation with UK firms allegedly either incapable or unwilling to exploit inventions December 4th, 2013
Technology and Fashion industries need to come together for future of wearable tech: Beecham Research calls for convergence of aesthetics and technology in new video published today: Wearable Technology: Towards Function with Style December 4th, 2013
Curing Cancer with Magnetic Nanoparticles December 4th, 2013
Turning waste into power with bacteria ó and loofahs December 4th, 2013
Agilent Technologies Introduces Next-Generation Atomic Force Microscope December 3rd, 2013
Agilent Technologiesí Award-Winning, Ultrafast Express Test Now Compatible with All G200 Stages and DCM II, XP Heads December 3rd, 2013
AXT Appointed Exclusive Distributor for Fischione Instruments November 29th, 2013
New Malvern data demonstrate monoclonal antibody characterization using the Viscotek SEC-MALS 20 November 27th, 2013